The common occurrence of β-amyloid deposition in the setting of clinical DLB may prove more difficult in terms of differentiation from AD, although as discussed above, the assessment of imaging for dopamine transporters seems to assist with the differential diagnosis from AD[66]. The gene discussed is SLC6A3; the disease is Lewy body dementia.